Literature DB >> 35695911

Drug repurposing-an emerging strategy in cancer therapeutics.

Khadija Shahab Turabi1, Ankita Deshmukh1, Sayan Paul2, Dayanand Swami1, Shafina Siddiqui1, Urwashi Kumar1, Shreelekha Naikar1, Shine Devarajan1, Soumya Basu3, Manash K Paul4, Jyotirmoi Aich5.   

Abstract

Cancer is a complex disease affecting millions of people around the world. Despite advances in surgical and radiation therapy, chemotherapy continues to be an important therapeutic option for the treatment of cancer. The current treatment is expensive and has several side effects. Also, over time, cancer cells develop resistance to chemotherapy, due to which there is a demand for new drugs. Drug repurposing is a novel approach that focuses on finding new applications for the old clinically approved drugs. Current advances in the high-dimensional multiomics landscape, especially proteomics, genomics, and computational omics-data analysis, have facilitated drug repurposing. The drug repurposing approach provides cheaper, effective, and safe drugs with fewer side effects and fastens the process of drug development. The review further delineates each repurposed drug's original indication and mechanism of action in cancer. Along with this, the article also provides insight upon artificial intelligence and its application in drug repurposing. Clinical trials are vital for determining medication safety and effectiveness, and hence the clinical studies for each repurposed medicine in cancer, including their stages, status, and National Clinical Trial (NCT) identification, are reported in this review article. Various emerging evidences imply that repurposing drugs is critical for the faster and more affordable discovery of anti-cancerous drugs, and the advent of artificial intelligence-based computational tools can accelerate the translational cancer-targeting pipeline.
© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Antibacterial drugs (antibiotics); Artificial Intelligence; COX inhibitor (NSAIDs); Cancer; Drug repurposing; HMG-CoA reductase inhibitors (statins); Metformin

Mesh:

Substances:

Year:  2022        PMID: 35695911     DOI: 10.1007/s00210-022-02263-x

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.195


  144 in total

Review 1.  Aspirin.

Authors:  E H Awtry; J Loscalzo
Journal:  Circulation       Date:  2000-03-14       Impact factor: 29.690

2.  The utility of Aspirin in Dukes C and High Risk Dukes B Colorectal cancer--the ASCOLT study: study protocol for a randomized controlled trial.

Authors:  Raghib Ali; Han-Chong Toh; Whay-Kuang Chia
Journal:  Trials       Date:  2011-12-14       Impact factor: 2.279

Review 3.  Breast cancer: Biology, biomarkers, and treatments.

Authors:  Khadijeh Barzaman; Jafar Karami; Zeinab Zarei; Aysooda Hosseinzadeh; Mohammad Hossein Kazemi; Shima Moradi-Kalbolandi; Elahe Safari; Leila Farahmand
Journal:  Int Immunopharmacol       Date:  2020-04-29       Impact factor: 4.932

4.  Effect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.

Authors:  Rebecca Aft; Michael Naughton; Kathryn Trinkaus; Mark Watson; Lourdes Ylagan; Mariana Chavez-MacGregor; Jing Zhai; Sacha Kuo; William Shannon; Kathryn Diemer; Virginia Herrmann; Jill Dietz; Amjad Ali; Matthew Ellis; Peter Weiss; Timothy Eberlein; Cynthia Ma; Paula M Fracasso; Imran Zoberi; Marie Taylor; William Gillanders; Timothy Pluard; Joanne Mortimer; Katherine Weilbaecher
Journal:  Lancet Oncol       Date:  2010-03-31       Impact factor: 41.316

Review 5.  Inflammation and cancer: back to Virchow?

Authors:  F Balkwill; A Mantovani
Journal:  Lancet       Date:  2001-02-17       Impact factor: 79.321

6.  Itraconazole inhibits angiogenesis and tumor growth in non-small cell lung cancer.

Authors:  Blake T Aftab; Irina Dobromilskaya; Jun O Liu; Charles M Rudin
Journal:  Cancer Res       Date:  2011-09-06       Impact factor: 12.701

7.  Celecoxib: a novel treatment for lung cancer.

Authors:  Hussein Abou-Issa; Galal Alshafie
Journal:  Expert Rev Anticancer Ther       Date:  2004-10       Impact factor: 4.512

Review 8.  The oncogene ERG: a key factor in prostate cancer.

Authors:  P Adamo; M R Ladomery
Journal:  Oncogene       Date:  2015-04-27       Impact factor: 9.867

9.  New drugs are not enough‑drug repositioning in oncology: An update.

Authors:  Romina Gabriela Armando; Diego Luis Mengual Gómez; Daniel Eduardo Gomez
Journal:  Int J Oncol       Date:  2020-01-20       Impact factor: 5.650

Review 10.  Artemisinins as a novel anti-cancer therapy: Targeting a global cancer pandemic through drug repurposing.

Authors:  Yolanda Augustin; Henry M Staines; Sanjeev Krishna
Journal:  Pharmacol Ther       Date:  2020-10-16       Impact factor: 12.310

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.